A Study of [14C]-LY3023703 in Healthy Participants

July 30, 2018 updated by: Eli Lilly and Company

Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects

This type of study is called a radiolabeled study. For this study, LY3023703 (study drug) has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered to healthy men. Information about any side effects that may occur will also be collected. This study will last up to 15 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

18

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Wisconsin
      • Madison, Wisconsin, United States, 53704
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Participants will either be sterile or, if sexually active, agree to use approved methods of contraception from the day before dosing until 3 months after the follow-up assessment
  • Participants will refrain from sperm donation from the day before dosing until 3 months after the follow-up assessment
  • Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/m^2)
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • Have given written informed consent approved by Lilly and the IRB governing the site

Exclusion Criteria:

  • Are currently enrolled in, have participated, within the last 30 days, in a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Are participants who have previously completed or withdrawn from this study or any other study investigating LY3023703, and have previously received the investigational product
  • Have known allergies to LY3023703, related compounds or any components of the formulation, or history of significant atopy
  • Have recent or ongoing gastrointestinal (GI) symptoms or illnesses, have a history of GI bleeding or perforation, related to previous nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase (COX)2 inhibitor therapy or have active or history of recurrent peptic ulcer/hemorrhage (2 or more distinct episodes of proven ulceration or bleeding)
  • Have a history of intolerance to NSAIDs or aspirin
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of alanine aminotransferase or aspartate aminotransferase levels above the normal ranges, confirmed on repeat, or a history of elevated and abnormal liver tests
  • Have intended use of over-the-counter medications or prescription medication within 14 days prior to dosing. Also within 30 days prior to dosing, any drugs and dietary items that are known inducers or inhibitors of cytochrome P450 (CYP) 3A or CYP2J2 or other drugs that may affect the disposition of LY3023703 or increase risk for complications from the study
  • Have consumed herbal supplements within 14 days prior to admission or grapefruit juice, grapefruits, grapefruit-containing products, Seville orange juice, Seville oranges, star fruit, or star fruit juice within 7 days prior to dosing or intend to consume during the study
  • Have donated blood of more than 500 milliliter (mL) within the last month
  • Have participated in a [14C]-study within the last 6 months prior to admission for this study
  • Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
  • A positive alcohol breathalyzer test
  • A positive cotinine test
  • Are unwilling to refrain from consuming xanthine-containing food and drink from 48 hours prior to admission until discharge from the Clinical Research Unit (CRU)
  • Have a defecation pattern less than once per 2 days or acute constipation within 3 weeks of the day before dosing
  • In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: [^14C]-LY3023703
Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
Administered orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Fecal Excretion of LY3023703 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time Frame: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Urinary Excretion of LY3023703 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time Frame: Predose up to 168 hours post dose
Predose up to 168 hours post dose

Secondary Outcome Measures

Outcome Measure
Time Frame
Pharmacokinetics of LY3023703 and Radioactivity Maximum Observed Concentration (Cmax)
Time Frame: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Pharmacokinetics of LY3023703 and Radioactivity Time of Maximum Observed Concentration (Tmax)
Time Frame: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Pharmacokinetics of LY3023703 and Radioactivity Area Under The Concentration-Time Curve From Time Zero to the Last Timepoint With a Measurable Concentration [AUC (0 to Tlast)]
Time Frame: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Relative Abundance of LY3023703 and the Metabolites of LY3023703 in Urine and Feces
Time Frame: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Relative Abundance of LY3023703 and the Metabolites of LY3023703 in Plasma
Time Frame: One hour post-dose up to 72 hours post dose
One hour post-dose up to 72 hours post dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2013

Primary Completion (Actual)

October 1, 2013

Study Completion (Actual)

October 1, 2013

Study Registration Dates

First Submitted

October 16, 2013

First Submitted That Met QC Criteria

October 16, 2013

First Posted (Estimate)

October 18, 2013

Study Record Updates

Last Update Posted (Actual)

August 28, 2018

Last Update Submitted That Met QC Criteria

July 30, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 15097
  • I6H-MC-MCBD (Other Identifier: Eli Lilly and Company)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.